S. 1095Introduced
Stop STALLING Act
Makes filing objectively baseless FDA petitions to block competing drug approvals an unfair method of competition in the generic drug market
Plain-English overview
What this bill does
Makes filing objectively baseless FDA petitions to block competing drug approvals an unfair method of competition in the generic drug market
Key points
- Prohibit baseless FDA petitions
- Authorize FTC lawsuits
- Increase civil penalties
Current status
Where it stands
Status
Introduced
Latest action
2025-04-10 — Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
Related context
Topics and policy areas
undefinedAdministrative remediesBusiness ethicsCivil actions and liabilityCompetition and antitrustDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)